Abstract

For cancer gene therapy, cancer-specific over- expression of a therapeutic gene is required to reduce side effects derived from expression of the gene in normal cells. To develop such an expression vector, we searched for genes over-expressed and/or specifically expressed in cancer cells using bioinformatics and have selected genes coding for protein regulator of cytokinesis 1 (PRC1) and ribonuclease reductase 2 (RRM2) as candidates. Their cancer-specific expressions were confirmed in both breast cancer cell lines and patient tissues. We compared each promoter's cancer-specific activity in the breast normal and cancer cell lines using the luciferase gene as a reporter and confirmed cancer-specific expression of both PRC1 and RRM2 promoters. To test activities of these promoters in viral vectors, the promoters were also cloned into an adeno-associated viral (AAV) vector containing green fluorescence protein (GFP) as the reporter. The GFP expression levels by these promoters were various depending on cell lines tested and, in MDA-MB-231 cells, GFP activities derived from the PRC1 and RRM2 promoters were as strong as that from the cytomegalovirus (CMV) promoter. Our result showed that a vector containing the PRC1 or RRM2 promoter could be used for breast cancer specific overexpression in gene therapy.

Highlights

  • Gene therapy is an attractive treatment to correct defective genes that cause genetic diseases or to kill cancer cells

  • We tested whether protein regulator of cytokinesis 1 (PRC1) or ribonuclease reductase 2 (RRM2) promoter could be employed for the development of breast cancer-enhanced gene expression

  • Both PRC1 and RRM2 proteins were highly expressed in the breast cancer cell lines, MCF7 and T47D, compared to their expressions in MCF10A normal cells

Read more

Summary

Introduction

Gene therapy is an attractive treatment to correct defective genes that cause genetic diseases or to kill cancer cells . From more than two decades of research, it is obvious that a successful gene therapy requires several critical components (Lo et al, 2005). A cancer gene therapy regime needs a good therapeutic gene that can kill cancer cells, arrest angiogenesis, inhibit tumor growth or activate cellular immune potential. It requires a safe and efficient system that can deliver a therapeutic gene into the specific cancer cells and a promoter that exhibits both cancer-specific and strong expression.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call